Base Editing in Clinical Trials to Treat Acute Lymphoblastic Leukemia

January 23rd, 2024|Categories: Perspectives on Current Science|

Base editing has experienced a rapid rise in use since it first came on the scene in 2016, with multiple trials underway, testing its ability to treat conditions with precise, single-letter changes to DNA. The technique presents a potentially more accurate and safer method ...

Fanzor: A Programmable RNA-Guided System In Eukaryotes Similar to CRISPR

September 5th, 2023|Categories: Perspectives on Current Science|

Researchers have uncovered the first programmable RNA-guided system in eukaryotes that could be even more precise than CRISPR gene-editing. The discovery — led by Feng Zhang at the McGovern Institute for Brain Research at MIT and the Broad Institute of MIT and Harvard — demonstrates ...

Investigating the Biology and Potential of CircRNA

August 2nd, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

In the past few years, mRNA has become a mainstream word with the swift creation of mRNA vaccines to treat SARS-CoV-2. This new technology was already in development, placing it in the perfect position to meet an urgent global need. Yet, there are still ...

Hydrogels and Nucleic Acids – An Innovative Combination

July 10th, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

An incredible amount of time, effort, and money have gone into finding increasingly better ways to safely and effectively deliver nucleic acid based therapeutics. Many solutions have been developed that do indeed provide safe and effective delivery, and we have had many occasions to celebrate ...

The Oligonucleotide Therapeutics Society is Pleased to Announce the 2023 Annual Meeting in Barcelona, Spain

June 29th, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

The Oligonucleotide Therapeutics Society (OTS) is excited to bring together those in the field of oligonucleotide therapeutics for its 19th Annual Oligo Meeting. Anyone interested in oligonucleotide therapeutics is welcome to join the event, which will be held virtually and in person on Oct. 22-25, ...

Exa-cel: A Potential Breakthrough with Astounding Results

June 27th, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

A new therapy that uses the Nobel Prize-winning CRISPR technology may be the latest breakthrough in gene editing therapy. Exagamglogene autotemcel (exa-cel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, addresses two debilitating blood disorders: sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). If approved, it ...

Delivering Oligonucleotide Drugs to the Lungs in a World of Influenza, Coronaviruses, Asthma, and Chronic Lung Diseases

June 13th, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

There are many different respiratory viruses, from influenza and respiratory syncytial virus (RSV) to coronaviruses, parainfluenza viruses, rhinoviruses, and adenoviruses. Some are highly pathogenic and can trigger respiratory failure and death. These viruses also facilitate secondary bacterial infections, often resulting in pneumonia, meningitis, and other ...

Martin Egli and Muthiah Manoharan’s Review of Approved Oligonucleotide Therapeutics

May 25th, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Martin Egli and Muthiah Manoharan recently co-wrote an outstanding review that is a great resource for anyone in our community. The review, titled “Chemistry, structure and function of approved oligonucleotide therapeutics,” is a collection of information about the eighteen nucleic acid therapeutics that have ...

Go to Top